Haemophilus influenzae causes communityacquired respiratory tract and invasive infections in humans. Resistance to macrolides and fluoroquinolones is emerging in H. influenzae limiting its therapeutic options. In the present study we demonstrated in vitro and in vivo potential of this novel ketolide against H. influenzae.
Background:
Haemophilus influenzae causes communityacquired respiratory tract and invasive infections in humans. Resistance to macrolides and fluoroquinolones is emerging in H. influenzae limiting its therapeutic options. In the present study we demonstrated in vitro and in vivo potential of this novel ketolide against H. influenzae.
Methods & Materials: MIC of fresh clinical isolates of H. influenzae (n=145) (␤-lactamase producer, non-producer strains and standard ATCC quality control strains) from tertiary care centers in India was evaluated using microbroth dilution method (CLSI). Bactericidal potential was evaluated using time kill kinetics method against 3 strains. Immunocompromised mouse and rat pneumonia model were performed against 2 clinical isolates of H. influenzae. Plasma and ELF concentrations were estimated using standard HPLC analysis and Microbiological method.
Results: Ketolide A showed MIC range of 0.03 -4 g/ml against fresh clinical isolates of H. influenzae. Ketolide A was bactericidal against 3 different strains of H. influenzae at 4X MIC concentration and the results were comparable with telithromycin. Ketolide A showed >1 log 10 reduction in the CFU/lungs compared to 2 h control at 100 mg/kg BW PO bid in rat and mouse immunocompromised pulmonary infection models. The efficacy of ketolide A correlated with its accumulation in rat lung tissue much above its MIC levels (1-2 g/ml) upto 8h.
Conclusion: Efficacy of ketolide A in rodent H. influenzae models and high concentration in ELF and lung tissue warrants its further investigation for the treatment of H. influenzae infections. Background: Macrolides used in clinic are associated with number of shortcomings. Our research efforts were directed towards identification of novel macrolides that will address these issues.
Methods & Materials:
We report herein, modifications at 3'-N and C-2 position of the macrolide ring system. A series of ketolides and 2-fluoro-ketolides 11, 12-cyclic carbamates in which one of the methyl of the 3'-N,N-dimethyl group was replaced by the other alkyl group were synthesized and evaluated against relevant macrolide-sensitive and macrolide resistant respiratory pathogens.
Results: Excellent in-vitro activities with MIC range of 0.008-0.125 against gram positive S.pneumoniae and 0.06 -16g/ml against macrolide resistant S.pneumoniae strains were demonstrated for some of the C2-fluoroketolides. Few of them also showed excellent activity against S aureus and S. pyogenes strains. Modulation of the activity was also observed with modification on 3'-N position.
Conclusion: We have synthesized novel series of ketolide and C2-fluoroketolide antibiotics that exhibited good in-vitro activity against the macrolide resistant pathogens including lab generated telithromycin resistant S.pneumoniae strains. Moreover, the structure activity relationship study of these compounds led to the discovery of a novel fluoroketolide lead. 
